97 related articles for article (PubMed ID: 11878766)
1. Initial studies of the molecular basis of peptide mimicry of group B streptococcal type III capsular polysaccharide.
Pincus SH; Lepage SR; Jung RF; Massey JG; Jaseja M
Int Rev Immunol; 2001; 20(2):221-7. PubMed ID: 11878766
[TBL] [Abstract][Full Text] [Related]
2. Peptides that mimic the group B streptococcal type III capsular polysaccharide antigen.
Pincus SH; Smith MJ; Jennings HJ; Burritt JB; Glee PM
J Immunol; 1998 Jan; 160(1):293-8. PubMed ID: 9551983
[TBL] [Abstract][Full Text] [Related]
3. NMR studies of carbohydrates and carbohydrate-mimetic peptides recognized by an anti-group B Streptococcus antibody.
Johnson MA; Jaseja M; Zou W; Jennings HJ; Copie V; Pinto BM; Pincus SH
J Biol Chem; 2003 Jul; 278(27):24740-52. PubMed ID: 12700231
[TBL] [Abstract][Full Text] [Related]
4. Fisher scientific award lecture - the capsular polysaccharides of Group B Streptococcus and Streptococcus suis differently modulate bacterial interactions with dendritic cells.
Segura M
Can J Microbiol; 2012 Mar; 58(3):249-60. PubMed ID: 22356626
[TBL] [Abstract][Full Text] [Related]
5. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
[TBL] [Abstract][Full Text] [Related]
6. Anti-idiotypic vaccination against group B streptococci.
Beninati C; Oggioni M; Mancuso G; Midiri A; Polonelli L; Pozzi G; Teti G
Int Rev Immunol; 2001; 20(2):263-73. PubMed ID: 11878769
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen.
Paoletti LC; Peterson DL; Legmann R; Collier RJ
Vaccine; 2001 Nov; 20(3-4):370-6. PubMed ID: 11672899
[TBL] [Abstract][Full Text] [Related]
8. Structural and immunochemical characterization of the type VIII group B Streptococcus capsular polysaccharide.
Kogan G; Uhrín D; Brisson JR; Paoletti LC; Blodgett AE; Kasper DL; Jennings HJ
J Biol Chem; 1996 Apr; 271(15):8786-90. PubMed ID: 8621515
[TBL] [Abstract][Full Text] [Related]
9. Specificity and protective activity of murine monoclonal antibodies directed against the capsular polysaccharide of type III group B streptococci.
Teti G; Calapai M; Calogero G; Tomasello F; Mancuso G; Galli A; Riggio G
Hybridoma; 1992 Feb; 11(1):13-22. PubMed ID: 1371105
[TBL] [Abstract][Full Text] [Related]
10. The group B streptococcal capsular carbohydrate: immune response and molecular mimicry.
Feldman RG; Rijkers GT; Hamel ME; David S; Zegers BJ
Adv Exp Med Biol; 1998; 435():261-9. PubMed ID: 9498084
[No Abstract] [Full Text] [Related]
11. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.
Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Edwards MS; Kasper DL
J Infect Dis; 2004 Mar; 189(6):1103-12. PubMed ID: 14999615
[TBL] [Abstract][Full Text] [Related]
12. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
Paoletti LC; Rench MA; Kasper DL; Molrine D; Ambrosino D; Baker CJ
Infect Immun; 2001 Nov; 69(11):6696-701. PubMed ID: 11598040
[TBL] [Abstract][Full Text] [Related]
13. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Wallerström G; Holmgren J
Vaccine; 2001 May; 19(25-26):3360-8. PubMed ID: 11348699
[TBL] [Abstract][Full Text] [Related]
14. Fine specificity and cross-reactions of monoclonal antibodies to group B streptococcal capsular polysaccharide type III.
Pincus SH; Moran E; Maresh G; Jennings HJ; Pritchard DG; Egan ML; Blixt O
Vaccine; 2012 Jul; 30(32):4849-58. PubMed ID: 22634296
[TBL] [Abstract][Full Text] [Related]
15. Peptide mimics of two pneumococcal capsular polysaccharide serotypes (6B and 9V) protect mice from a lethal challenge with Streptococcus pneumoniae.
Smith CM; Lo Passo C; Scuderi A; Kolberg J; Baxendale H; Goldblatt D; Oggioni MR; Felici F; Andrew PW
Eur J Immunol; 2009 Jun; 39(6):1527-35. PubMed ID: 19499518
[TBL] [Abstract][Full Text] [Related]
16. Quantitative determination of antibodies to type III group B streptococcal polysaccharide.
Guttormsen HK; Baker CJ; Edwards MS; Paoletti LC; Kasper DL
J Infect Dis; 1996 Jan; 173(1):142-50. PubMed ID: 8537651
[TBL] [Abstract][Full Text] [Related]
17. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
[TBL] [Abstract][Full Text] [Related]
18. Properties of human anti-group B streptococcal type III capsular IgG antibody.
Feldman RG; Breukels MA; David S; Rijkers GT
Clin Immunol Immunopathol; 1998 Feb; 86(2):161-9. PubMed ID: 9473378
[TBL] [Abstract][Full Text] [Related]
19. Immunoblot analysis of bacterial polysaccharides: application to the type-specific polysaccharides of Streptococcus suis and Streptococcus agalactiae.
Tikkanen K; Häyrinen J; Pelkonen S; Finne J
J Immunol Methods; 1995 Dec; 187(2):233-44. PubMed ID: 7499882
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the linkage between the type III capsular polysaccharide and the bacterial cell wall of group B Streptococcus.
Deng L; Kasper DL; Krick TP; Wessels MR
J Biol Chem; 2000 Mar; 275(11):7497-504. PubMed ID: 10713053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
